About this Course
UConn has developed web-based continuing pharmacy education activities to enhance the practice of pharmacists and assist pharmacists in making sound clinical decisions to affect the outcome of anticoagulation therapy for the patients they serve. There are a total of 12 hours of CPE credit available. Successful completion of these 12 hours (13 activities) or equivalent training will prepare the pharmacist for the Anticoagulation Traineeship, which described below in the Additional Information Box.
The activities below are available separately for $17/hr or as a bundle price of $140 for all 13 activities (12 hours). These are the pre-requisites for the anticoagulation traineeship. Any pharmacist who wishes to increase their knowledge of anticoagulation may take any of the programs below.
When you are ready to submit quiz answers, go to the Blue "Take Test/Evaluation" Button.
Target Audience
Pharmacists who are interested in making sound clinical decisions to affect the outcome of anticoagulation therapy for the patients they serve.
This activity is NOT accredited for technicians.
Pharmacist Learning Objectives
At the end of this knowledge-based continuing education activity, the learner will be able to:
- Discuss the pharmacology of heparin, low molecular weight heparin and fondaparinux.
- Discuss the indications and contraindications for heparin, low molecular weight heparin and fondaparinux.
Release Date
Released: 06/01/2022
Expires: 05/31/2025
Course Fee
$8.50
ACPE UAN
ACPE #0009-0000-22-029-H01-P
Session Code
22AC29-KWX83
Accreditation Hours
0.5 hour of CE
Bundle Options
If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.
You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.
Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE) $140.00
In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.
Additional Information
Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT
The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.
Accreditation Statement
The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of credit for the online activity ACPE #0009-0000-22-029-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.
Grant Funding
There is no grant funding for this activity.
Requirements for Successful Completion
To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.
Type in your NABP ID, DOB and the session code for the activity. You were sent the session code in your confirmation email.
Faculty
Jenna Lee, PharmD
Supervisor
Ambulatory Care Clinical Pharmacy Services
Yale New Haven Hospital
New Haven, CT
Faculty Disclosure
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
Dr. Lee has no relationship with an ineligible company and therefore has nothing to disclose.
Disclaimer
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Program Content
Program Handouts
Post Test Evaluation
View Questions for Heparin, Low Molecular Weight Heparin and Fondaparinux Questions
1. You get a phone call from a nurse, concerned that her patient with a new blood clot and being treated with heparin is going for dialysis today. She is unsure of how this will affect the patient’s heparin therapy. You respond:
a. You advise the nurse the patient will require an additional bolus dose of heparin after dialysis.
b. As heparin is contraindicated in patient’s on dialysis, you contact the doctor and get the order changed to LMWH.
c. You advise the nurse that dialysis will not affect heparin levels and it is safe to continue therapy without any intervention.
d. You advise the nurse to increase the heparin rate during dialysis.
e. As heparin is contraindicated in patient’s on dialysis, you contact the doctor and get the order changed to argatroban.
2. The following is true regarding low molecular weight heparins, except:
a. LMWH share a common pentasaccharide sequence that enables binding to antithrombin and thrombin
b. Protamine will not completely reverse LMWH effects
c. Dose adjustments are necessary for CrCl <30 ml/min
d. Due to longer half life, once or twice daily dosing is possible
e. All of the above are true
3. Low molecular weight heparins are approved for all of the following indications, except:
a. Prevention of venous thromboembolism
b. Treatment of venous thromboembolism
c. Anticoagulation in patients with a history of HIT
d. Acute coronary syndromes
e. All of the above
4. TY, a 70 year old male is admitted to your hospital with an community acquired pneumonia. He is started on IV antibiotics, albuterol nebulizers, and IV fluids. He has no allergies. His INR on admission is 1.1. His BUN/Scr = 30/2.5 He is 5’5” and 75 kg. On interdisciplinary rounds, the attending physician asks for any pharmacological recommendations for this patient. You suggest that VTE prophylaxis should be considered if the patient does not have any contraindications to it. The patient does not have any contraindications, and the physician asks for your recommendation for choice of therapy. The most appropriate recommendation is:
a. Enoxaparin 40mg SC daily
b. IV Heparin per thromboembolic protocol
c. Fondaparinux 2.5mg SC daily
d. Enoxaparin 30mg SC daily
e. Tinzaparin 13,125 anti Xa international units SC daily
5. The following are true about BOTH LMWH and fondaparinux, except:
a. Dose adjustment or avoidance of use is necessary in patients with impaired renal function
b. Anti Xa testing is recommended for most patients, and should be drawn on days 2 and 4 of therapy
c. Active bleeding is a contraindication for use
d. Both are associated with lower risk for development of HIT vs. heparin
e. Both are indicated for the treatment and prophylaxis of VTE
Additional Courses Available for Anticoagulation
Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour
Anticoagulation Management Pearls - 1 hour
Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour
Laboratory Monitoring of Anticoagulation – 1 hour
Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours
Developing an Anticoagulation Clinic – 1.0 hour
Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour
Risk Management in Anticoagulation – 1 hour
Perioperative Management of Warfarin Interruption – 1 hour
Hypercoagulable States – 1 hour
Challenging Topics in Anticoagulation – 1 hour
Available Strategies to Reverse Anticoagulation Medications - 1 hour
Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour
The University of Connecticut, School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 21.5 contact hours (2.15 CEUs) will be awarded to pharmacists who view the presentations, pass the quizzes with a grade of 70% or better, and complete all evaluations. (ACPE #0009-23-004-CP) Statements of credit will be electronically transmitted to CPE Monitor within 72 hours of completing the activity.
